Success Metrics

Clinical Success Rate
100.0%

Based on 16 completed trials

Completion Rate
100%(16/16)
Active Trials
0(0%)
Results Posted
50%(8 trials)

Phase Distribution

Ph phase_2
2
13%
Ph phase_3
2
13%
Ph phase_1
12
75%

Phase Distribution

12

Early Stage

2

Mid Stage

2

Late Stage

Phase Distribution16 total trials
Phase 1Safety & dosage
12(75.0%)
Phase 2Efficacy & side effects
2(12.5%)
Phase 3Large-scale testing
2(12.5%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

16 of 16 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

16

all time

Status Distribution
Completed(16)

Detailed Status

Completed16

Development Timeline

Analytics

Development Status

Total Trials
16
Active
0
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 112 (75.0%)
Phase 22 (12.5%)
Phase 32 (12.5%)

Trials by Status

completed16100%

Recent Activity

0 active trials
Showing 5 of 16
completedphase_1

A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Pancreatic Cancer

NCT02231723
completedphase_1

A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer

NCT02024607
completedphase_1

A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies

NCT01325441
completedphase_3

A Study of BBI608 Plus Weekly Paclitaxel to Treat Gastric and Gastro-Esophageal Junction Cancer

NCT02178956
completedphase_1

A Study of BBI608 in Combination With Temozolomide in Adult Patients With Recurrent or Progressed Glioblastoma

NCT02315534
View all 16 trials

Clinical Trials (16)

Showing 16 of 16 trials
NCT02231723Phase 1

A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Pancreatic Cancer

Completed
NCT02024607Phase 1

A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer

Completed
NCT01325441Phase 1

A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies

Completed
NCT02178956Phase 3

A Study of BBI608 Plus Weekly Paclitaxel to Treat Gastric and Gastro-Esophageal Junction Cancer

Completed
NCT02315534Phase 1

A Study of BBI608 in Combination With Temozolomide in Adult Patients With Recurrent or Progressed Glioblastoma

Completed
NCT02279719Phase 1

A Study of BBI608 in Combination With Sorafenib, or BBI503 in Combination With Sorafenib in Adult Patients With Hepatocellular Carcinoma

Completed
NCT01776307Phase 2

A Study of BBI608 in Adult Patients With Advanced Colorectal Cancer

Completed
NCT01775423Phase 1

A Study of BBI608 in Adult Patients With Advanced Malignancies

Completed
NCT02467361Phase 1

A Study of BBI608 Administered in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Cancers

Completed
NCT02352558Phase 1

A Study of BBI608 in Adult Patients With Advanced, Refractory Hematologic Malignancies

Completed
NCT02432326Phase 1

A Study of BBI608 and BBI503 Administered in Combination to Adult Patients With Advanced Solid Tumors

Completed
NCT01830621Phase 3

BBI608 and Best Supportive Care vs Placebo and Best Supportive Care in Pretreated Advanced Colorectal Carcinoma

Completed
NCT02641873Phase 1

A Study of BBI608 Administrated With FOLFIRI + Bevacizumab in Adult Patients With Metastatic Colorectal Cancer

Completed
NCT02358395Phase 1

A Study of BBI608 Administrated With Sorafenib in Adult Patients With Advanced Hepatocellular Carcinoma

Completed
NCT02347917Phase 1

A Study of BBI608 in Combination With Pemetrexed and Cisplatin in Adult Patients With Malignant Pleural Mesothelioma

Completed
NCT03647839Phase 2

Modulation Of The Tumour Microenvironment Using Either Vascular Disrupting Agents or STAT3 Inhibition in Order to Synergise With PD1 Inhibition in Microsatellite Stable, Refractory Colorectal Cancer

Completed

All 16 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
16